Trial suggests GLP-1 combo therapy cuts fat while preserving muscle in obesity

A recent research study found that a combination of the GLP-1 receptor agonist semaglutide and bimagrumab, an antibody that blocks activin signaling pathways, results in greater weight loss while also preserving lean mass, such as skeletal muscle…

Continue Reading

News Source: medicalxpress.com